Anti-Von Willebrand Factor 抗体 (ab11713)
Key features and details
- Sheep polyclonal to Von Willebrand Factor
- Suitable for: Immunodiffusion, ELISA, ICC/IF, IHC-Fr, Flow Cyt
- Reacts with: Mouse, Human, Pig
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-Von Willebrand Factor antibody
Von Willebrand Factor 一次抗体 製品一覧 -
製品の詳細
Sheep polyclonal to Von Willebrand Factor -
由来種
Sheep -
アプリケーション
適用あり: Immunodiffusion, ELISA, ICC/IF, IHC-Fr, Flow Cytmore details
適用なし: IHC-P -
種交差性
交差種: Mouse, Human, Pig -
免疫原
Full length native protein (purified) corresponding to Human Von Willebrand Factor. Purified human von Willebrand factor prepared from citrated human plasma
Database link: P04275 -
特記事項
This product should be stored undiluted. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
バッファー
pH: 7.40
Preservative: 0.09% Sodium azide
Constituents: Glycine buffered saline, 0.1% EACA, 0.01% Benzamidine, 0.0292% EDTA -
Concentration information loading... -
精製度
Ion Exchange Chromatography -
特記事項（精製）
Purified IgG was prepared from serum by ion exchange chromatography. -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab11713の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Immunodiffusion |
Use at an assay dependent concentration.
|
|
| ELISA |
Use at an assay dependent concentration.
|
|
| ICC/IF | (2) |
Use at an assay dependent concentration.
|
| IHC-Fr | (6) |
Use at an assay dependent concentration.
|
| Flow Cyt |
Use at an assay dependent concentration.
ab37385 - Sheep polyclonal IgG, is suitable for use as an isotype control with this antibody. |
| 特記事項 |
|---|
|
Immunodiffusion
Use at an assay dependent concentration. |
|
ELISA
Use at an assay dependent concentration. |
|
ICC/IF
Use at an assay dependent concentration. |
|
IHC-Fr
Use at an assay dependent concentration. |
|
Flow Cyt
Use at an assay dependent concentration. ab37385 - Sheep polyclonal IgG, is suitable for use as an isotype control with this antibody. |
追加情報
Is unsuitable for IHC-P.
ターゲット情報
-
機能
Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. -
組織特異性
Plasma. -
関連疾患
Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. -
配列類似性
Contains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains. -
ドメイン
The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules. -
翻訳後修飾
All cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated. -
細胞内局在
Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules. - Information by UniProt
-
参照データベース
- Entrez Gene: 7450 Human
- Entrez Gene: 22371 Mouse
- Omim: 613160 Human
- SwissProt: P04275 Human
- SwissProt: Q8CIZ8 Mouse
- Unigene: 440848 Human
- Unigene: 22339 Mouse
-
別名
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
see all
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (115)
ab11713 は 115 報の論文で使用されています。
- Jeon SB et al. CD34dim cells identified as pluripotent stem cell-derived definitive hemogenic endothelium purified using bone morphogenetic protein 4. Cell Prolif 56:e13366 (2023). PubMed: 36478274
- Lye P et al. Effects of bacterial and viral pathogen-associated molecular patterns (PAMPs) on multidrug resistance (MDR) transporters in brain endothelial cells of the developing human blood-brain barrier. Fluids Barriers CNS 20:8 (2023). PubMed: 36721242
- Huang L et al. FGL2 deficiency alleviates maternal inflammation-induced blood-brain barrier damage by blocking PI3K/NF-κB mediated endothelial oxidative stress. Front Immunol 14:1157027 (2023). PubMed: 37051251
- Thota LNR et al. The Pulmonary Endothelial Glycocalyx Modifications in Glypican 1 Knockout Mice Do Not Affect Lung Endothelial Function in Physiological Conditions. Int J Mol Sci 24:N/A (2023). PubMed: 37834029
- Di Pietro P et al. Targeting the ASMase/S1P pathway protects from sortilin-evoked vascular damage in hypertension. J Clin Invest 132:N/A (2022). PubMed: 35104805